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ABSTRACT 
Phosphofructokinase (PFK) catalyzes the phosphorylation of fructose 6-phosphate 
(F6P) to fructose 1,6-bisphosphate (F16BP) in a MgATP dependent reaction. This reaction 
represents the first committed step of the glycolytic pathway and as such, plays an 
important role in metabolism. In liver, this regulation is especially interesting, as 
hepatocytes can alternatively undergo gluconeogenesis or glycolysis. While PFKs from 
the livers of several mammalian species have been characterized, human liver PFK has 
not been thoroughly examined. The gene encoding human liver PFK was cloned into an 
expression vector utilizing the tac promoter. Human liver PFK was expressed in an 
Escherichia coli strain, RL257a, which contains no native PFK. The protein has been 
purified to a specific activity of 130 U/mg through a combination of heat denaturation, 
ammonium sulfate precipitation, anion exchange chromatography, and gel filtration 
chromatography. Human liver PFK is inhibited by MgATP with a coupling free energy 
(ΔGax) of 3.0 kcal/mol, as compared to rat liver PFK (ΔGax 2.3 kcal/mol), a well 
characterized mammalian PFK. Additionally, human liver PFK demonstrates greater than 
10-fold increase in F6P affinity when the pH is increased as demonstrated by the 
dissociation constants at pH 6 (Kia 0.70) and pH 9 (Kia 0.032). At the cellular concentration 
of 3 mM MgATP, F16BP activates the enzyme (ΔGax -0.69 kcal/mol), while citrate 
inhibits the enzyme (ΔGax 0.62 kcal/mol). The additional activators ammonium sulfate 
(ΔGax -2.0 kcal/mol) and AMP also impact the activity of HLPFK. These results suggest 
that the human liver enzyme is less sensitive to allosteric effectors than the rat liver 
enzyme, with the possible exception of MgATP. 
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CHAPTER I  
INTRODUCTION 
Phosphofructokinase (PFK) catalyzes the first committed step of the glycolytic 
pathway and, as such, plays an important role in glucose metabolism. PFK transfers the γ-
phosphate group of adenosine triphosphate (ATP) to fructose-6-phosphate (F6P) to form 
fructose-1,6-bisphosphate (F16BP) and adenosine diphosphate (ADP). An accurate 
picture of glucose metabolism regulation is critical to understanding a number of diseases, 
including some cancers,1–5 diabetes,6,7 Tarui disease,8 and Down’s Syndrome.9,10 
PFK is present in both prokaryotic and eukaryotic cells. Prokaryotic PFKs have 
been studied from a wide variety of organisms for many years. In general, they are 
activated by MgADP and inhibited by phosphoenolpyruvate (PEP), which both act as K-
type allosteric effectors; that is, they modify substrate affinity without affecting the 
maximal velocity of PFK. Eukaryotic PFK investigations have focused on the enzyme 
from Saccharomyces sp. or from mammalian tissues. In mammals, three isoforms of PFK 
are differentially present in a tissue-specific manner. These three isozymes have been 
identified as: PFK-L (liver), PFK-M (muscle), and PFK-C (platelet).11–16 These isozymes 
associate into homo and heterotetramers in a tissue specific fashion. In liver, PFK 
predominantly forms a homotetramer of L-type subunits although PFK-M and PFK-C are 
also present.11,14–16  
As a key control point in the glycolytic pathway, mammalian PFK activity is 
regulated by a variety of cellular effectors and by self-association to form higher order 
oligomers.17–21 As a prerequisite to understanding cellular regulation, it is important to 
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measure the physiological concentrations of relevant molecules, including substrates, 
products, and allosteric effectors. PFK in hepatocytes is present at 20-50 µg/mL17 and the 
intracellular concentrations of several effectors, ATP (3 mM20,22), F6P (0.02 mM-0.06 
mM20,22), AMP (0.3 mM23), F16BP (20 µM22), citrate (0.2 mM24), and ammonia (0.6 
mM25), modify PFK activity.24  
The study of specific mammalian PFKs began with the purification of rabbit 
muscle by the Lardy group.26 They purified PFK from rabbit muscle tissues and  
completed initial kinetic studies, in addition to identifying the stabilizing effect of MgATP 
on purified rabbit muscle PFK. Additional groups studied PFKs from a variety of sources, 
as reviewed by Uyeda in 197927 and recently by Schöneberg28 and Sola-Penna.29 These 
reviews summarize purification, regulation, mechanism, and structures of both eukaryotic 
and prokaryotic PFKs. 
Rabbit muscle PFK is inhibited by a substrate, ATP, at a second binding site and  
activated by products, ADP and F16BP. Additionally, citrate and lactate inhibit while 
AMP, cAMP, F26BP, and acetyl CoA activate rabbit muscle PFK.29–32 These molecules 
all represent cellular indicators of metabolic needs. In addition to direct regulation by 
metabolites, it has been demonstrated that these molecules can modify the quaternary 
structure of the enzyme.17–20 ATP, citrate, and lactate (in muscle, but not liver) interact 
with PFK in a manner that favors dissociation of the tetramer and diminishes PFK activity 
when cellular energy levels are high. ADP, F6P, and AMP favor association of the 
tetramer, allowing for increased PFK activity under energy-poor conditions. While muscle 
PFK shares a 68.6% amino acid sequence identity with liver PFK, the regulation of muscle 
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PFK is different than liver PFK. While both muscle and liver can PFKs self-associate, the 
concentration of PFK in muscle (0.45-2 mg/g33) is much higher than in liver (12-30 µg/g17) 
leading to different association behavior between the PFK isoforms present in specific 
tissue types. The understanding of higher order structures is convenient for the 
development of purification technique with a notable example of active higher-order 
oligomers being exploited during the purification of RLPFK. Reinhart24 demonstrated that 
in the presence of F6P, RLPFK elutes from a Sepharose 2B column in the void volume, 
indicating a molecular weight greater than 40,000 kD. This allowed for efficient separation 
from smaller molecules. 
In addition to direct effects by metabolites and quaternary structure, liver PFK 
activity is indirectly modified by the action of the hormone glucagon34–37 through the 
presence of glucagon receptors on the surface of the hepatocytes. Glucagon binds to 
receptors and activates a signal transduction pathway utilizing a G protein which in turn 
activates adenylate cyclase. Adenylate cyclase generates cAMP which then caused protein 
kinase A to phosphorylate phosphofructokinase-2/fructose 2,6-bisphosphatase. The 
phosphorylation activates the fructose 2,6-bisphosphatase domain, which degrades 
intracellular fructose-2,6-bisphosphate (F26BP), leading to a decrease in glycolysis 
through reduction of activation of PFK. Fructose-2,6-bisphosphate is a potent allosteric 
activator of liver PFKs38–42 and plays a critical role in liver PFK accurately responding to 
cellular energetic needs.  
Structural studies of mammalian PFKs have included electron microscopy and 
crystallography, among other techniques. Electron micrographs of human muscle PFK 
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showed tetramers at 18Å resolution.43 Rabbit muscle PFK has formed crystals which have 
diffracted with increasing resolution, the most recent of which was published in 2011 with 
a resolution of 3.2Å (3O8L),44 while human muscle PFK was crystallized in 2014 and the 
structure determined at 6.0Å (4OMT).45 Human PFK-C has also been crystallized, with 
and without ligands, by Kloos et al (4XZ2)46 and Webb et al (4XYK),47 both in 2015. The 
structure of liver PFK has remained elusive for structural biochemists, possibly due to the 
formation of undefined higher order oligomers.21,48,49 The published structures have 
presented a homodimer, half of the physiological homotetramer, in addition to identifying 
some of the ligand binding sites.  
 The gene for human liver phosphofructokinase was identified as part of 
chromosome 2150 with the cDNA sequence published in 1989.51 Initial investigations 
focused on identification of tissues expressing HLPFK. The molecular weight of each 
human PFK-L subunit was determined to be 85kD.16 While human muscle PFK has been 
expressed and crystallized,45 there is minimal kinetic data available for human liver PFK. 
This work seeks to provide new data regarding the expression, purification, and 
characterization of human liver phosphofructokinase. 
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CHAPTER II  
MATERIALS AND METHODS 
Materials 
The gene for HLPFK was ordered from Biomatik, Cambridge, ON, based on the 
amino acid sequence of HLPFK shown in Figure 1. The company used proprietary 
methods to synthesize codon-optimized hlpfk for expression in Escherichia coli cells. The 
pUC19 plasmid was purchased from New England Biolabs and the pALTER-EX1 plasmid 
was purchased from Promega. The E. coli strain, RL257a, is a tonA- derivative of RL257.52 
Reagents and kits for molecular biology techniques were from New England Biolabs and 
Qiagen.  
 
 
MAAVDLEKLR ASGAGKAIGV LTSGGDAQGM NAAVRAVTRM GIYVGAKVFL IYEGYEGLVE 
GGENIKQANW LSVSNIIQLG GTIIGSARCK AFTTREGRRA AAYNLVQHGI TNLCVIGGDG 
SLTGANIFRS EWGSLLEELV AEGKISETTA RTYSHLNIAG LVGSIDNDFC GTDMTIGTDS 
ALHRIMEVID AITTTAQSHQ RTFVLEVMGR HCGYLALVSA LASGADWLFI PEAPPEDGWE 
NFMCERLGET RSRGSRLNII IIAEGAIDRN GKPISSSYVK DLVVQRLGFD TRVTVLGHVQ 
RGGTPSAFDR ILSSKMGMEA VMALLEATPD TPACVVTLSG NQSVRLPLME CVQMTKEVQK 
AMDDKRFDEA TQLRGGSFEN NWNIYKLLAH QKPPKEKSNF SLAILNVGAP AAGMNAAVRS 
AVRTGISHGH TVYVVHDGFE GLAKGQVQEV GWHDVAGWLG RGGSMLGTKR TLPKGQLESI 
VENIRIYGIH ALLVVGGFEA YEGVLQLVEA RGRYEELCIV MCVIPATISN NVPGTDFSLG 
SDTAVNAAME SCDRIKQSAS GTKRRVFIVE TMGGYCGYLA TVTGIAVGAD AAYVFEDPFN 
IHDLKVNVEH MTEKMKTDIQ RGLVLRNEKC HDYYTTEFLY NLYSSEGKGV FDCRTNVLGH 
LQQGGAPTPF DRNYGTKLGV KAMLWLSEKL REVYRKGRVF ANAPDSACVI GLKKKAVAFS 
PVTELKKDTD FEHRMPREQW WLSLRLMLKM LAQYRISMAA YVSGELEHVT RRTLSMDKGF 
Figure 1: Primary Sequence of HLPFK. 
 
 
 
Reagents and enzymes were from the following sources: ATP, AMP, F6P, and 
F16BP (sodium salts), DTT, aldolase and triose phosphate isomerase (ammonium sulfate 
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suspensions), MOPS, TRIS base, CHES, MES, and citric acid, Sigma-Aldrich; Luria-
Bertani media (Miller), BD Bioscience; NADH, and tetracycline, Research Products 
International Corp.; IPTG, Fisher Scientific; glycerol-3-phosphate dehydrogenase, lactate 
dehydrogenase, and pyruvate kinase (ammonium sulfate suspensions), PEP 
(monopotassium salt), Roche; MonoQ, HiQ, and Sepharose 2B resins, Pharmacia (now 
GE Healthcare); Reducing Agent Compatible Pierce BCA Protein Assay Kit, 
ThermoFisher; All chemicals and reagents were of the highest purity available. Deionized, 
distilled water was used for all experiments.  
Molecular Biology 
The hlpfk gene was initially supplied in a pUC19 plasmid. The plasmid was 
digested using BamHI and EcoRI and subject to electrophoresis on a 1% agarose gel. The 
gel containing the hlpfk gene was extracted and the DNA was purified using the QIAquick 
Gel Extraction Kit. The pALTER-EX1 plasmid was similarly digested, although not 
subject to electrophoresis. The hlpfk gene was ligated into the vector using T4 DNA Ligase 
at room temperature overnight. The ligated sample was heat inactivated at 65°C for 10 
min and transformed into chemically competent (calcium treated) JM109 E. coli cells. 
Transformants were grown at 37°C overnight. The plasmids from selected colonies were 
sequenced by Eton Sequencing to confirm construction. 
The addition of the ribosome binding site to the plasmid for enhanced cellular 
expression of hlpfk began with the design of primers. Primers were chosen to amplify the 
gene from the initial pALTER-EX1 construct. Figure 2 contains the primers constructed 
for polymerase chain reaction (PCR) amplification. The gene was amplified using 
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PhusionHF Polymerase. The thermal cycle was programmed for 10s at 98°C for initial 
denaturation, followed by 34 cycles of 10s at 98°C for denaturation, 30s at 56°C for 
annealing, 90s at 72°C for extension, and 10 min at 72°C for the final extension. The 
resulting PCR amplicons were cleaned up using a QIAquick PCR Purification Kit and 
then digested with BamHI and EcoRI for 2 hr at 37°C. The pALTER-EX1 plasmid was 
also digested with BamHI and EcoRI. After digestion, both vector and amplicon were 
cleaned with the QIAquick PCR Purification Kit and treated with Antarctic Phosphatase. 
After another pass through the QIAquick PCR Purification Kit, the amplicon was ligated 
into the vector using T4 DNA Ligase at room temperature for two hours. The ligated 
sample was heat inactivated, transformed into JM109 E. coli cells, grown, and sequenced 
as above.  
 
 
 
Forward: 5’ GTACAGGATCCTAAGGAGGCAGGAAAC ATG GCA GCG GTT GAC CTG G 3’ 
 
Reverse: 5’ GTACAGAATTCATTA GAA ACC TTT GTC CAT AGA C 3’ 
 
Figure 2: Primer Construction. Underlined bases represent restriction enzyme sites 
(BamHI forward, EcoRI reverse). The red bases are the optimized ribosome binding site, 
and the bolded bases represent the hlpfk gene.  
 
 
 
Kinetic Analysis 
Maximal velocity enzyme assays were performed in a cuvette containing 0.6 mL 
of reaction mixture (50 mM Tris-HCl pH 8.5, 100 mM KCl, 0.1 mM EDTA, 20 mM 
(NH4)2SO4, 5 mM DTT, 400 µg aldolase, 40 µg triose phosphate isomerase, and 40 µg 
glycerol-3-phosphate dehydrogenase). The coupling enzymes, aldolase, triose phosphate 
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isomerase, and glycerol-3-phosphate dehydrogenase, are present to oxidize NADH and to 
prevent F16BP accumulation. Therefore consumption of F6P is coupled to change in 
absorbance at 340nm by a two-fold turnover of NADH to NAD+ as shown in Figure 3A. 
This assay allows for increased sensitivity to PFK activity. 
 
 
 
Figure 3: Coupled Assay Systems. (A) represents the coupling enzymes used in all 
assays except those examining F16BP while (B) represents the coupling enzyme system 
used to examine the effect of F16BP.  
  
 
 
 The allosteric properties of the enzyme were investigated in a cuvette containing 
0.6 mL of the reaction mixture (50 mM MOPS-KOH pH 7.0, 100 mM KCl, 0.1 mM 
EDTA, 5 mM DTT, 5 mM MgCl2, 400 µg aldolase, 40 µg triose phosphate isomerase, and 
40 µg glycerol-3-phosphate dehydrogenase). MgATP, F6P, and allosteric effectors are 
varied as indicated. For experiments studying the effect of pH on HLPFK, MES-KOH 
(pKa 6.1) at pH 6.0, Tris-HCl (pKa 8.1) at pH 8.0, or CHES-KOH (pKa 9.5) at pH 9.0 was 
substituted for MOPS-KOH.  
In order to study the effect of F16BP, it is necessary to use alternate coupling 
enzymes, pyruvate kinase and lactate dehydrogenase, and 1 mM PEP as shown in Figure 
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3B. When the total formation of F16BP is very low (<10 µM), this system allows for 
analysis of the coupling between F6P and F16BP at different MgATP concentrations. 
While the aldolase, triose phosphate isomerase, and glycerol-3-phosphate dehydrogenase 
system generates two NAD+ molecules for each F6P molecule consumed, the pyruvate 
kinase and lactate dehydrogenase system generates one NAD+ molecule.  
All assays conducted in this work were completed on a Beckman Series 600 
spectrophotometer at 25°C. Coupling enzymes were desalted prior to use by extensive 
dialysis against the experimental buffer to remove ammonium sulfate. From the coupled 
assay conditions, the change in absorbance is related to the change in substrate 
concentration as related by Beer’s Law (εNADH 6.22 mM-1 cm-1). By limiting the substrate 
to a total decrease of less than 10%, the assay measures the initial rate under steady state 
conditions. The measurement of initial rates at low substrate concentrations allows for 
more accurate rate determinations.  
The initial rates, reported as specific activity (Units/mg protein, where one unit 
represents 1µmol F16BP or ADP per minute), are plotted as a function of substrate 
concentration and fit to the Hill equation (Equation 1) to determine K1/2 under rapid 
equilibrium conditions. Fitting data to Equation 1 using different concentrations of 
effectors provides the basis to calculate the coupling between two ligands. Figure 4 
illustrates the shift in the graph when the effector is an activator (A) or an inhibitor (B). 
v0 =
Vmax[S]
n
K1/2
n + [S]n
       (1) 
After initial rate data is fit to the Hill equation, the K1/2 values are plotted as a 
function of effector. In order to quantify the allosteric effect of a ligand, the 
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thermodynamic linkage analysis of protein-ligand interactions initially described by 
Weber53 serves as a basis for extended analysis used by Reinhart.54–56  
 
 
 
Figure 4: Simulated K1/2 Shifts with Allosteric Effector. (A) represents the K1/2 shift 
for an activator while (B) demonstrates the K1/2 shift for an inhibitor. 
 
 
 
 
Figure 5: Single Substrate, Single Modifier Scheme. The dissociation constants 
defined in the text are indicated in red beside the relevant rate constants.  
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The linkage model suggests four enzyme forms shown in Figure 5: E (free 
enzyme), EA (enzyme with substrate), XE (enzyme with allosteric effector), and XEA 
(enzyme with both substrate and allosteric effector). From the kinetic rate constants, we 
can define thermodynamic dissociation constants: Kia
0=
k2
k1
, Kia
∞=
k8
k7
, Kix
0=
k6
k5
, and 
Kix
∞=
k12
k11
 where the superscript ‘0’ indicates the absence of the second ligand and the 
superscript ‘∞’ indicates saturation with the second ligand. From these dissociation 
constants we can quantify the magnitude of the allosteric effect by defining the coupling 
quotient: 
Qax =
Kia
0
Kia
∞ =
Kix
0
Kix
∞     (2) 
 
 
 
 
Figure 6: Simulated Coupling. An activator is represented in (A) while an inhibitor is 
represented in (B).  
 
 
 
When the rapid equilibrium assumption is valid, K1/2 can be plotted as a function 
of effector. Graphically, the coupling quotient is equal to the ratio of the bottom to top 
 12 
 
plateaus, shown in Figure 6. When the coupling quotient is equal to 1, there is no allosteric 
effect. For values less than 1, the allosteric effector acts as an inhibitor while values greater 
than 1 indicate an allosteric activator.  When K1/2 is plotted as a function of effector 
concentration (X), the data are described by Equation 3:  
K1/2 = Kia
0 Kix
0 +X
Kix
0 +Qax(X)
      (3) 
Determination of the coupling quotient (Qax) allows calculation of the coupling free 
energy based on the relationships shown in Equation 5: 
∆Gax = −RT lnQax      (4) 
When the rapid equilibrium assumption is valid and steady state rates are 
measured, Qax represents the equilibrium constant for the disproportionate equilibrium 
shown in Equation 5. This analysis calculates thermodynamic parameters from kinetic 
measurements, setting the stage for simple comparisons across multiple systems.  
EA + XE 
Qax
↔ XEA + E     (5) 
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CHAPTER III 
RESULTS 
Growth and Expression 
In order to begin studying HLPFK, the first step was to determine a successful 
expression and purification procedure. Using the amino acid sequence in Figure 1, the E. 
coli codon-optimized hlpfk was ordered from Biomatik. The synthesized cDNA was 
initially located in a pUC19 plasmid; upon arrival, the gene was cloned into pALTER-
EX1. The pALTER-EX1 plasmid contains tetr, which permits growth in tetracycline; 
expression is controlled by the tac promoter and hlpfk is inducible with isopropyl β-D-1-
thiogalactopyranoside (IPTG). The protein was expressed in a derivative of RL257,52 with 
the tonA gene knocked out to prevent infection by phage. 
Early preps expressed little HLPFK, despite different growth temperatures (37°C, 
30°C, or some combination thereof), different growth times, and different concentrations 
of IPTG. Based on the suggestion of Dr. Jennifer Herman, an optimized ribosome binding 
site (RBS), TAAGGAGG,57 was substituted for the RBS already present (AGGA). As 
shown in Table 1, the addition of the optimized RBS increased the expression by almost 
five-fold.  
Cells were grown under selective pressure by tetracycline by inoculating 6 L of 
Luria-Bertani media (Miller) with 6 mL of an overnight culture grown to stationary phase 
(also with tetracycline). Cultures were incubated at 30°C while shaking at 250 rotations 
per minute until an optical density of 0.6 at 600 nm is reached; then they are induced with 
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1 mM IPTG and incubated at 30°C while shaking at 250 rpm for a total growth time of 30 
hr. This growth typically yields approximately 20g wet weight of cells with about 450U/g.  
 
 
Table 1: HLPFK Expression. 
 Total Units (U) Wet Weight of Cells (g) U/g 
HLPFK 814 7.45 109 
HLPFK + RBS 2910 6.25 465 
 
 
 
Purification 
As the challenges in expression were investigated, two similar purifications that 
both yielded purified HLPFK were developed. Both purification protocols were adapted 
from previous work with RLPFK.24 The major differences lie in the initial purification 
buffer (Purification I used a phosphate buffer with F6P while Purification II used a tris 
buffer with ATP), the ammonium sulfate procedure (Purification I fractionates with 
ammonium sulfate while Purification II continues with proteins that precipitate at 33%), 
and the anion exchange protocol and buffers (Purification I used a MonoQ resin with a 
higher ionic strength buffer while Purification II used a HiQ resin and lower ionic strength 
buffer). Purification I yielded a protein with a specific activity of 105 U/mg while 
Purification II yielded a sample with a specific activity of 130 U/mg. HLPFK requires F6P 
or MgATP in all buffers to maintain activity.  
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Purification I 
Cells were resuspended in purification buffer (20 mM KPi pH 7.6, 3 mM MgSO4, 
5 mM DTT, 0.1 mM EDTA, 1 mM F6P) with 1 mM phenylmethanesulfonyl fluoride 
(PMSF), then sonicated to lyse cells. Sonication was completed by pulsing for 15 sec and 
resting for 45 sec for a total pulse time of 10 min. The crude lysate was centrifuged for 30 
min at 20000 g at 4°C. The sonication typically yields a crude lysate with a specific activity 
of 0.63 U/mg. 
The supernatant was then heated to 55±1°C for 3 min by slowly swirling the 
solution in a flask immersed intermittently in a boiling water bath. After the heat 
denaturation, the solution was rapidly cooled to less than 10°C by swirling the flask in an 
ice-water bath. The heat denatured lysate was centrifuged for 30 min at 20000 g at 4°C 
and the supernatant generally has a specific activity of 1.3 U/mg. The heat denatured 
supernatant was then fractionated with ammonium sulfate. Ammonium sulfate was added 
to supernatant slowly, while stirring on ice, and then the entire solution was maintained at 
4°C for 90 min without stirring. Pellets were harvested by centrifugation for 20 min at 
9000 g at 4°C. The greatest activity was found in the pellet containing proteins precipitated 
between 45% and 50% ammonium sulfate. The resuspension of that pellet yielded a 
specific activity of 11 U/mg. 
The precipitated proteins are dialyzed against the column buffer A (50 mM Tris-
HCl pH 8.0, 100 mM KCl, 20 mM (NH4)2SO4, 5 mM DTT, 0.1 mM EDTA, 3 mM MgCl2, 
1 mM F6P), then diluted to about 1 mg/mL and loaded to a pre-equilibrated MonoQ anion 
exchange column. The column was washed with column buffer A, then proteins were 
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eluted with a gradient of column buffer B, which is the same as column buffer A with the 
addition of 1 M NaCl. The NaCl gradient has three steps, the first from 0-10%, the second 
from 10-25%, and the third step from 25-100%. Fractions were assayed for activity and 
selectively pooled to generate the highest specific activity. Figure 7A shows the elution 
profile from the MonoQ. The pooled fractions had a specific activity of 22 U/mg. 
 
 
 
Figure 7: Elution Profiles of Purification I. (A) MonoQ elution profile where protein 
is indicated by the absorbance at 280 nm shown in blue. The red line indicates the 
molarity of NaCl and the black box represents the pooled fractions. (B) Sepharose 2B 
elution profile where protein is indicated by the absorbance at 280 nm (blue) and the 
activity of the sample is shown in red. The black box indicates pool. 
 
 
 
The sample was concentrated with 55% ammonium sulfate and resuspended to a 
volume of about 2 mLs in purification buffer, then loaded to a 344 mL (1.7 cm x 38.6 cm) 
Sepharose 2B column and eluted with purification buffer. Fractions were again assayed 
for activity and selectively pooled for purity. Purified protein was dialyzed into and then 
maintained in storage buffer (20 mM KPi pH 7.6, 3 mM MgSO4, 5 mM DTT, 0.1 mM 
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EDTA, 1 mM F6P, and 20% glycerol (w/v)) for up to two months before activity 
decreased. Figure 7B shows the elution profile from the gel filtration.  
Protein concentration was determined for each sample by precipitating protein 
with 20% trichloroacetic acid and then using the Pierce BCA Assay Kit. Purity was 
evaluated by SDS-PAGE. Figure 8 is a 10% SDS PAGE gel showing the purity of each 
purification step and the final product. The purification steps are summarized in Table 2.  
 
 
Table 2: Summary of HLPFK Purification I. 
Sample 
Vol 
(mL) 
Activity 
(U/mL) 
Protein 
(mg/mL) 
Specific 
Activity 
(U/mg) 
Total 
Units 
(U) 
Yield 
(%) 
Purification 
Fold 
Cleared Lysate 96 12 20 0.63 1190 100 1 
Heat 
Denaturation 
90 14 11 1.3 1260 106 2 
(NH4)2SO4 
Precipitate 
13 46 4.2 11 580 49 18 
MonoQ 32 20 0.90 22 633 53 35 
Sepharose 2B 2.8 72 0.70 105 201 17 167 
 
 
 
 
Figure 8: SDS-PAGE of Purification I. The lanes of this 10% SDS-PAGE show (1) 
molecular weight marker, (2) cleared lysate, (3) heat denaturation, (4) ammonium sulfate 
precipitate, (5) dilute MonoQ pool, (6) empty, and (7) purified HLPFK. 
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Purification II 
Cells were resuspended in buffer (50 mM Tris-HCl pH 8, 50 mM NaF, 1 mM ATP, 
and 5 mM DTT) with 1 mM PMSF, then sonicated and centrifuged, as in Purification I. 
The sonication typically yielded a crude lysate with a specific activity of 4.4 U/mg. The 
crude lysate was then heat denatured as in Purification II to generate supernatant with a 
specific activity of 8.7 U/mg, which was then precipitated with 33% ammonium sulfate. 
Ammonium sulfate was added to supernatant slowly, while stirring on ice, and then the 
entire solution was maintained at 4°C for 90 min without stirring. The pellet was harvested 
by centrifugation for 20 min at 9000 g at 4°C and the resuspended pellet yielded a specific 
activity of 25 U/mg. 
 
 
 
Figure 9: Elution Profiles of Purification II. (A) HiQ elution profile with absorbance 
at 280nm in blue, activity in red, NaCl gradient in yellow, and pooled fractions indicated 
by the black box. (B) Sepharose 2B elution profile with absorbance at 280nm in blue, 
enzyme activity in red, and the black box indicates pooled fractions.  
 
 
 
The precipitated proteins were dialyzed against a modified column buffer A from 
that used in Purification I (50 mM Tris-HCl pH 8.0, 5 mM DTT, 0.1 mM EDTA, 5 mM 
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MgCl2, 1 mM F6P, and 0.02% NaN3), then diluted to about 1 mg/mL and loaded to a pre-
equilibrated HiQ anion exchange column. The column was washed with modified column 
buffer A, then proteins were eluted with a gradient of modified column buffer B, which is 
the same as the modified column buffer A with the addition of 1 M NaCl. The NaCl 
gradient was modified from Purification I: the first step was from 0-10%, the second step 
was from 10-56%, and the third step was from 56-100%.  
 
 
Table 3: Summary of HLPFK Purification II. 
Sample 
Vol 
(mL) 
Activity 
(U/mL) 
Protein 
(mg/mL) 
Specific 
Activity 
(U/mg) 
Total 
Units 
(U) 
Yield 
(%) 
Purification 
Fold 
Cleared Lysate 100 41 9.5 4.4 4220 100 1 
Heat 
Denaturation 
94 39 4.5 8.7 3650 86 2 
(NH
4
)
2
SO
4
 
Precipitate 
95 25 0.99 25 2350 56 6 
HiQ 130 11 0.21 51 1350 32 12 
Sepharose 2B 0.50 220 1.7 130 670 16 29 
 
 
 
The elution profile is shown in Figure 9A. The black box indicates the pooled 
fractions (specific activity 51 U/mg), which were subsequently concentrated with 55% 
ammonium sulfate and then resuspended in about 2mL of gel buffer (20 mM KPi pH 7.6, 
3 mM MgSO4, 5 mM DTT, 0.1 mM EDTA, 1 mM F6P) and applied to the same Sepharose 
2B column. The elution profile for the gel filtration procedure is shown in Figure 9B. The 
pooled fractions (black box) had a specific activity of 130 U/mg. Purified protein was 
dialyzed into and then maintained in storage buffer (20 mM KPi pH 7.6, 3 mM MgSO4, 5 
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mM DTT, 0.1 mM EDTA, 1 mM F6P, and 20% glycerol (w/v)) for up to two months 
before decreased activity was observed, as in Purification I. 
Purification II is summarized by Table 3 and Figure 10. Protein concentrations 
were determined using the Reducing Agent Compatible Pierce BCA Protein Assay Kit.  
 
 
 
Figure 10: SDS-PAGE of Purification II. Lanes are (1) molecular weight marker, (2) 
cleared lysate, (3) heat denatured sample, (4) 33% ammonium sulfate pellet, (5) HiQ 
pool, (6) Sepharose 2B load, (7) pooled Sepharose 2B pool.  
 
 
 
General Usage Guidelines for Purified Protein 
HLPFK requires either MgATP or F6P to be present in storage conditions to 
remain active. The protein also requires DTT to be active. When measuring initial rates of 
HLPFK, it is important to allow the protein to incubate at room temperature for at least 
thirty min between initial dilution and kinetic measurements. 
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Comparison with Rat Liver Phosphofructokinase  
Once HLPFK was purified, the first experiments examined the effects of the two 
substrates, F6P and MgATP. By measuring the K1/2 for F6P at various concentrations of 
MgATP, the coupling free energy between F6P and MgATP was calculated. This analysis 
was repeated for RLPFK to compare the two enzymes. Purified RLPFK was obtained from 
David Holland. The data is shown in Figure 11 and the fit parameters from Equation 3 are 
listed in Table 4. 
 
 
 
Figure 11: Comparison of HLPFK and RLPFK F6P and ATP binding at pH 7. 
Human liver PFK is represented by red, while rat liver PFK is represented by the blue. 
Both data sets were fit to Equation 3. 
 
 
 
Table 4: Comparison of HLPFK and RLPFK at pH 7 at 25°C. 
 
Kia
0  (mM) 
(F6P) 
Kix
0  (mM) 
(ATP) 
Qax ΔGax(kcal/mol) 
HLPFK 0.41 ± 0.02 0.21 ± 0.01 0.0060 ± 0.004 3.0 ± 0.4 
RLPFK 0.81 ± 0.3 0.43 ± 0.03 0.019 ± 0.002 2.3 ± 0.1 
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Graphically, we can see that HLPFK (red) and RLPFK (blue) have similar shapes. 
HLPFK binds F6P and MgATP tighter than RLPFK, as evidenced by the changes in the 
y-intercept (Kia
0 ) and the beginning of the upward transition (Kix
0 ), although the coupling 
free energy between F6P and MgATP is larger than RLPFK (as evidenced by the 
difference in the upper and lower plateau, Qax). With a difference in coupling free energy 
of 0.7 ± 0.4 kcal/mol, the coupling between F6P and MgATP is different for rat and human 
liver PFKs.   
Effect of pH 
 During the purification, it was observed that HLPFK was easier to saturate with 
F6P at higher pH. The maximal velocity assay was conducted at pH 8.5 for HLPFK, 
although for RLPFK the assay was conducted at pH 8.24 This observation led to the more 
systematic analysis of the effect of pH on the binding of F6P and MgATP shown in Figure 
12 and Table 5. In the table, Kia
0  represents F6P binding in the absence of MgATP while 
Kix
0  represents MgATP binding in the absence of F6P. 
As pH increases, HLPFK binds F6P more tightly, but MgATP binding doesn’t 
change between pH 7 and 8. HLPFK binds MgATP tighter at pH 6 than at other pH values 
from the data. The coupling free energy between F6P and MgATP binding does not appear 
to be pH dependent, as ΔGax does not change over the range examined.  
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Figure 12: MgATP and pH Effect on F6P Binding. The purple data was measured at 
pH 6.0, the red data measured at pH 7.0, the blue data measured at pH 8.0, and the green 
data measured at pH 9.0. 
 
 
 
Table 5: pH and MgATP Effect on F6P Binding at 25°C. 
pH 
Kia
0  (mM) 
(F6P) 
Kix
0  (mM) 
(ATP) 
Qax ΔGax(kcal/mol) 
6.0 0.70 ± 0.20 0.05 ± 0.01 0.0040 ± 0.0010 3.3 ± 0.2 
7.0 0.41 ± 0.02 0.21 ± 0.01 0.0060 ± 0.0004 3.0 ± 0.1 
8.0 0.100 ± 0.007 0.19 ± 0.01 0.0038 ± 0.0002 3.3 ± 0.1 
9.0 0.032 ± 0.005 0.14 ± 0.02 0.0033 ± 0.0005 3.4 ± 0.1 
 
 
Allosteric Effectors 
After comparing the binding of F6P and MgATP between RLPFK and HLPFK 
and over the range of pH values, the next experiments sought to examine changes in 
HLPFK activity in the company of different allosteric effectors. The lower limit of 0.3 
mM was chosen to eliminate the possibility of MgATP scarcity limiting the reaction rate. 
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The upper limit of 10 mM was chosen because at higher MgATP concentrations the K1/2 
for F6P becomes larger than can be reasonably measured.  
Fructose-1,6-Bisphosphate 
Fructose-1,6-bisphosphate is a product of the PFK reaction, which makes the 
investigation of the allosteric effect challenging. The coupling system described in Figure 
3A works by removing F16BP as quickly as possible and is therefore not useful in 
investigating this ligand. An alternate coupling system utilizing pyruvate kinase and 
lactate dehydrogenase (Figure 3B) was used instead and the reaction was only allowed to 
produce 10 µM F16BP in order to accurately measure the initial rates. 
 
 
 
Figure 13: MgATP and F16BP Effect on F6P Binding. Blue data was collected with 
10 mM MgATP present, green data was with 3 mM MgATP, purple data had 1 mM 
MgATP, and red data had 0. 3mM MgATP.  
 
 
Figure 13 demonstrates the modest activation effect of F16BP on F6P binding at 
four MgATP concentrations, 0.3 mM (red), 1 mM (purple), 3 mM (green), and 10 mM 
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(blue) while Table 6 contains the parameters obtained from fitting the data to Equation 3. 
In the table, Kia
0  represents F6P binding in the absence of F16BP while Kix
0  represents 
F16BP binding in the absence of F6P. From the data, we can see that as MgATP decreases, 
HLPFK binds F6P and F16BP tighter. The coupling free energy does not change 
dramatically between 1 and 10 mM MgATP, although at 1 mM MgATP the coupling free 
energy is decreased and there does not appear to be any coupling between F6P and F16BP 
at 0.3 mM MgATP. 
 
 
Table 6: F16BP and MgATP Effect on F6P Binding at 25°C. 
MgATP (mM) 
Kia
0  (mM) 
(F6P) 
Kix
0  (µM) 
(F16BP) 
Qax ΔGax(kcal/mol) 
10 13.4 ± 0.9 190 ± 90 3.4 ± 0.5 -0.72 ± 0.09 
3 6.9 ± 0.3 160 ± 70 3.2 ± 0.5 -0.69 ± 0.09 
1 0.93 ± 0.08 70 ± 80 2.3 ± 0.6 -0.49 ± 0.15 
0.3 N/A N/A N/A N/A 
 
 
 
Adenosine Monophosphate 
Adenosine monophosphate is a cellular indicator of low ATP that activates several 
PFKs and so it was selected as the next ligand in this study. Figure 14 contains the data 
from these experiments. The different colors represent the MgATP concentrations, 0.3 
mM (red), 1 mM (purple), 3 mM (green), and 10 mM (blue). The data show a slight 
activation before AMP begins to act as an inhibitor. Unfortunately this behavior prevented 
fitting to Equation 3.   
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At low MgATP concentrations it appears that AMP begins inhibiting F6P binding 
around 2 mM. This inhibition is less dramatic at higher MgATP concentrations and 
appears to require higher AMP concentrations for the inhibitory effect (10 mM AMP at 
10 mM MgATP). There is minimal activation observed at 10 mM MgATP with the other 
MgATP concentrations showing no coupling between F6P and AMP. This is especially 
interesting as AMP activates other mammalian PFKs (see discussion).  
 
 
 
Figure 14: MgATP and AMP Effect on F6P Binding. Blue data was collected with 10 
mM MgATP present, green data was with 3 mM MgATP, purple data had 1 mM 
MgATP, and red data had 0.3 mM MgATP. 
 
 
Citrate 
 Citrate is an intermediate of the Krebs cycle, which occurs after glycolysis in vivo, 
which directly inhibits mammalian PFKs. The effect of citrate on HLPFK activity was 
examined as a function of F6P concentration at different MgATP concentrations. Figure 
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15 shows the results of those experiments and Table 6 summarizes the parameters obtained 
by fitting the data to Equation 3. In the table, Kia
0  represents F6P binding in the absence of 
citrate while Kix
0  represents citrate binding in the absence of F6P. 
 
 
 
Figure 15: MgATP and Citrate Effect on F6P Binding. Blue data was collected with 
10 mM MgATP present, green data was with 3 mM MgATP, purple data had 1 mM 
MgATP, and red data had 0.3 mM MgATP. 
 
 
Table 7: Citrate and MgATP Effect on F6P Binding at 25°C. 
MgATP (mM) 
Kia
0  (mM) 
(F6P) 
Kix
0  (mM) 
(citrate) 
Qax ΔGax(kcal/mol) 
10 23.0 ± 0.6 40 ± 60 0.28 ± 0.66 0.75 ± 1.4 
3 5.8 ± 0.3 9 ± 4 0.35 ± 0.10 0.62 ± 0.17 
1 2.62 ± 0.09 12 ± 5 0.06 ± 0.07 1.7 ± 0.7 
0.3 0.92 ± 0.06 5 ± 2 0.20 ± 0.04 0.95 ± 0.12 
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From these data, where the concentration of MgATP is 0.3 mM (red), 1mM 
(purple), 3 mM (green), or 10 mM (blue), it is apparent that the binding of citrate does not 
depend on MgATP concentration, as evidenced by a constant Kix
0 . The coupling free 
energy between citrate and F6P does not depend on the concentration of MgATP.  
Ammonium Sulfate 
 After observing inconsistent data in early experiments that was eventually tracked 
to the preparation of coupling enzymes, the effect of ammonium sulfate on enzyme 
activity was examined. While not a physiological effector of HLPFK, many enzymes were 
supplied in ammonium sulfate suspensions and the effect on HLPFK is a technical 
consideration. 
 
 
 
 
Figure 16: MgATP and Ammonium Sulfate Effect on F6P Binding. Blue data was 
collected with 10 mM MgATP present, green data was with 3 mM MgATP, purple data 
had 1 mM MgATP, and red data had 0.3 mM MgATP. 
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Table 8: Ammonium Sulfate and MgATP Effect on F6P Binding at 25°C. 
MgATP (mM) 
Kia
0  (mM) 
(F6P) 
Kix
0  (mM) 
(ammonium sulfate) 
Qax ΔGax(kcal/mol) 
10 19 ± 3 10 ± 20 10 ± 10 -1.4 ± 0.6 
3 6.3 ± 0.4 20 ± 10 30 ± 10 -2.0 ± 0.2 
1 2.62 ± 0.09 17 ± 3 32 ± 3 -2.0 ± 0.1 
0.3 0.72 ± 0.05 8 ± 4 13 ± 3 -1.5 ± 0.1 
 
 
Similar to the figures containing other allosteric effectors, Figure 16 shows the 
effect of ammonium sulfate on F6P binding at 0.3 mM MgATP (red), 1 mM MgATP 
(purple), 3 mM MgATP (green), and 10 mM MgATP (blue). Table 8 summarizes the fit 
parameters from Equation 3. In the table, Kia
0  represents F6P binding in the absence of 
ammonium sulfate while Kix
0  represents ammonium sulfate binding in the absence of F6P. 
There may be an effect on ammonium sulfate binding due to MgATP, but it is difficult to 
interpret with the errors reported. The coupling free energy between ammonium sulfate 
and F6P appears to remain constant at the MgATP concentrations examined, although it 
decreases somewhat at 0.3 mM MgATP.  
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CHAPTER IV 
DISCUSSION AND CONCLUSIONS 
 Human liver phosphofructokinase is an important enzyme about which little has 
been published. Understanding the regulation of the first committed step of glycolysis in 
a cell that alternatively undergoes glycolysis and gluconeogenesis has implications for a 
variety of human diseases. Filling this gap in our knowledge begins with generating 
enzyme to study.  
 The first novelty of this work is the expression of HLPFK in an E. coli expression 
system. Utilizing the control of the tac promotor in pALTER-EX1 provided compatibility 
with the tonA, pfka, and pfkb deficient expression strain, RL257a. This strain was 
developed especially for expression of prokaryotic PFKs52 and has proven useful in the 
expression of HLPFK, as shown in this work. Early preps had as few as 100 units per gram 
wet weight of cells in the crude lysate; Purification I is an example of this procedure and 
while it produced enough enzyme for some kinetics, the investigation in a better 
expression system was ongoing.  
The addition of the optimized RBS improved expression by about five-fold, to 
about 450 units per gram wet weight of cells, and improved the purification. Increased 
expression provided the opportunity for more conservative pools to prioritize higher 
specific activity. The data presented as an example of Purification I were collected prior 
to the addition of the optimized RBS while Purification II data was collected using the 
new expression system.  
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Both protocols were adapted from the rat liver PFK procedure of Reinhart24 with 
minor changes. The differences between Purification I and Purification II were also minor. 
Differences were related to buffer components; HLPFK was always stored in the presence 
of either ATP or F6P. One efficiency introduced into Purification II was the modification 
of the ammonium sulfate precipitation. Fractionating the heated supernatant (as in 
Purification I) was time consuming while the alternative buffer (containing ATP instead 
of F6P) allows HLPFK to precipitate at 33% ammonium sulfate. In Purification I, the first 
day of purification ends at the ammonium sulfate step, but following Purification II, the 
proteins can be eluted and concentrated from the anion exchange column in day one. The 
anion exchange step was somewhat modified between the purifications. While the MonoQ 
and HiQ resins differ in capacity, the buffer in Purification I has a higher ionic strength 
than that in Purification II. This likely leads to weaker interactions between the protein 
and resin in Purification II, evidenced by the later elution of HLFPK. Finally, Purification 
II yielded a higher purity sample (130 U/mg) than Purification I (105 U/mg).  
The RLPFK procedure begins with rat livers24 while the HLPFK procedure begins 
with E. coli cells. RLPFK purification begins with an ATP-containing buffer while 
HLPFK can be purified with either ATP- or F6P-containing buffer. The heat denaturation 
occurs at 55 ± 1°C for HLPFK while 60 ± 1°C was used for RLPFK. Both 
chromatographic procedures utilized anion exchange chromatography; the HLPFK 
protocol used a MonoQ or HiQ resin on a fast flow liquid chromatography system while 
the RLPFK procedure utilized a DEAE cellulose resin. Both purifications used the same 
gel filtration resin as a polishing step. HLPFK purified from a bacterial expression system 
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has a specific activity of 130 U/g while the RLPFK purified from the natural source was 
purified to 85 U/g.24 Both proteins have a subunit molecular weight around 85000 Da as 
shown on SDS-PAGE gels.  
After purification, the comparison of human and rat liver PFKs was conducted 
with respect to MgATP and F6P at pH 7. HLPFK and RLPFK are very similar, with 96% 
sequence similarity and 88% sequence identity. The RLPFK used in this experiment was 
obtained from David Holland, who purified the enzyme from a bacterial expression system 
similar to that developed in this work. From the data in Figure 11, both enzymes show a 
similar effect of MgATP on F6P binding. Based on the coupling free energy, RLPFK has 
a smaller coupling than HLPFK. In comparing these data to previously published RLPFK, 
Reinhart reported the coupling free energy between MgATP and F6P of RLPFK to be 1.87 
kcal/mol.58 These values differ from the values in this report, and some of that difference 
may be explained by the different origin of the sample. The L-type PFK isozyme is not 
the only type present in hepatocytes, and as Reinhart purified RLPFK from natural 
sources, it is possible that PFK-M and PFK-C isozymes were also present in the sample, 
which may have some effect on the activity. Binding of F6P and MgATP was tighter in 
Reinhart’s purification (Kia
0  0.171 mM and Kix
0  0.31 mM)24 than the expressed RLPFK 
while Reinhart’s purification binds F6P tighter and MgATP less tightly than HLPFK. ATP 
inhibits HLPFK more that either RLPFK preparation and the recombinantly expressed 
RLPFK was more sensitive to inhibition by ATP than the RLPFK from natural sources as 
evidenced by the coupling free energies. 
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 The effect of MgATP inhibition was next investigated over a range of pH values. 
The data at pH 6 were poorly behaved compared to those collected at higher pH values. 
The more favorable F6P binding at higher pH was previously documented in rat liver, 
when Reinhart examined the coupling between MgATP and F6P over the pH range from 
5.5 to 9.58 For both HLPFK and RLPFK the Kia
0  decreases as pH increases. The MgATP 
binding remains similar except at low pH for both enzymes. Binding sensitivity to pH 
changes generally indicates changing protonation state of the binding site, leading to 
changes in the allosteric effect. In PFKs from E. coli and Bacillus stearothermophilus 
important active site residues include aspartic acid, arginine, histidine, and serine,59,60 all 
of which are affected by local pH. It seems likely that the F6P binding to HLPFK is 
dramatically influenced by the protonation states of active site residues. With regard to the 
coupling free energy of MgATP and F6P, it does not appear to be pH-dependent. It is 
interesting that the coupling between MgATP and F6P is not influenced by pH in HLFPK, 
as rabbit muscle PFK exhibits allostery over a range of pH values, but has no allosteric 
effects at pH 8.61,62  
 Despite being a product of the PFK reaction, F16BP activates HLPFK. The 
allosteric site for F16BP and F26BP has been suggested to evolve from a duplication event 
of the F6P site.28 The activation of HLPFK by F16BP was modest and somewhat 
influenced by the concentration of MgATP. The coupling free energy between F6P and 
F16BP appears to decrease slightly at 1 mM MgATP and disappear at 0.3 mM MgATP. 
In comparing this trend to RLPFK data, both enzymes show activation behavior. Reinhart 
demonstrated activation for the F16BP range from 0-250 µM, with the K1/2 changing 
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approximately five-fold.24 The HLPFK effect is less than the RLPFK with only a two-fold 
change at 3 mM MgATP. The concentration of F16BP in hepatocytes has been reported 
as 20 µM,22 a concentration that demonstrates limited activation alone for HLPFK. This 
suggests that some combination of ligands in necessary for activity under physiological 
conditions; F16BP does not activate sufficiently for cellular activity. 
 The next ligand studied was AMP, and it demonstrated the most unexpected data. 
AMP is well established as an activator of mammalian PFKs, including rat liver.24,62 
HLPFK showed minimal activation at 10mM MgATP and no activation at lower 
concentrations of MgATP. More surprisingly, inhibition was observed at higher 
concentrations of AMP, with the inhibitory behavior depending on the MgATP 
concentration. As the effects of AMP vary with MgATP concentration, it seems likely the 
bindings sites are linked in some way. In rabbit muscle PFK, this linkage has been 
demonstrated32 and implicated in Tarui disease.8 Hepatocytes contain approximately 0.3 
mM AMP;23 this study suggests that AMP is not sufficient to activate HLPFK in vivo and 
that the inhibition behavior observed may not have physiological relevance. 
 Citrate is a noted allosteric effector of mammalian PFKs and a downstream product 
of glycolysis that directly inhibits PFK. Citrate is present in hepatocytes at 0.2 mM, and 
Reinhart observed inhibition by citrate over the range from 0-5 mM.24 This study 
examined citrate between 0 and 90 mM and little inhibition was observed. Citrate and 
MgATP have been suggested to synergistically inhibit the mammalian PFKs, but the 
inhibition effect of citrate was not influenced by MgATP concentration. Citrate and F6P 
binding do not appear to influence each other. Citrate has been suggested to couple the 
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Krebs cycle to glycolysis and produce the Warburg effect, rather than the Pasteur effect.5 
The Warburg effect is a marker of cancerous cells where a high rate of glycolysis is 
observed under aerobic conditions which stands in direct contrast to the Pasteur effect, 
where pyruvate is converted to acetyl CoA in the presence of oxygen in order to facilitate 
oxidative phosphorylation. The effect of citrate on HLPFK in combination with other 
ligands is one of the next areas of investigation. 
The effect of ammonium sulfate was studied after it was determined that residual 
ammonium sulfate in the coupling enzyme preparation was affecting the repeatability of 
measurements. Additionally, activation by ammonia has been suggested as a method for 
increasing downstream formation of ATP and α-ketoglutarate, which are involved directly 
in ammonia fixation into glutamate and glutamine.14 The concentration of ammonia in 
hepatocytes has been cited as 0.6 mM,25 and this study examined the range from 0 to 100 
mM. The coupling free energy between F6P and ammonia changes little over the MgATP 
concentration range, suggesting the effect is independent of MgATP.  
 Liver PFK has consistently proved a challenging enzyme to study. In this work, 
the variation of the F6P binding in the absence of second ligand (Kia
0 ) in different 
experiments at the same MgATP concentration is telling. At 10 mM MgATP, the Kia
0  is 
about 15-20 mM while 3 mM MgATP presents a Kia
0  of about 6 mM. The Kia
0  at 1 mM 
MgATP is about 2 mM and at 0.3mM MgATP it is about 0.8 mM. These values were 
obtained with multiple enzyme preps, although the specific activity for all preps was in 
the range of 90-140 U/mg. The method of addition of MgATP and F6P to the reaction 
influenced the reproducibility of results. Assay cocktail and ligands were mixed prior to 
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the addition of enzyme, which began the measurements. The dependence on environment 
prior to assay may be related to the quaternary structure of the enzyme. As F6P favors 
higher order structures in RLPFK,21 it seems possible the enzyme begins to dissociate to 
the tetramer upon the addition of MgATP, or vice versa. The sensitivity of HLPFK to 
ligands and protein concentration made measurements challenging.  
The data presented herein represent the beginning of rigorous kinetic study of 
HLPFK. A successful growth and expression protocol was presented and initial kinetic 
characterizations are completed with the purified sample. These results suggest that the 
human liver enzyme is less sensitive to allosteric effectors than the rat liver enzyme, with 
the possible exception of MgATP. Future analyses will include the examination of F26BP 
effects and study on the oligomeric state of HLPFK in pursuit of the ultimate goal to 
determine how the enzyme functions in hepatocytes.  
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